Capstone Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capstone Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$232K	Buy	+2,909	New	+$186K	0.01%	1431
2016 Q1	–	Sell	-2,559	Closed	-$241K	–	1581
2015 Q4	$241K	Buy	+2,559	New	+$237K	0.01%	1411
2015 Q3	–	Sell	-1,749	Closed	-$210K	–	1594
2015 Q2	$210K	Buy	+1,749	New	+$209K	0.01%	1506
2013 Q4	–	Sell	-5,351	Closed	-$343K	–	1875
2013 Q3	$343K	Buy	+5,351	New	+$267K	0.01%	1571

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capstone Asset Management's ALNY Position: Q2 2017 in Review

Capstone Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2017: 2,909 shares worth $232K. The stake represents 0.01% of the portfolio and ranks #1431 among its holdings. This is a return to the name: Capstone Asset Management previously reported a position in ALNY as recently as Q4 2015.

Capstone Asset Management first reported a position in ALNY in Q3 2013 and has held it in 4 quarters since. The position peaked at $343K in Q3 2013. 226 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

Capstone Asset Management held 2,909 shares of Alnylam Pharmaceuticals worth $232K as of Q2 2017.
Alnylam Pharmaceuticals was a new Capstone Asset Management position in Q2 2017.
Alnylam Pharmaceuticals made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1431 holding.
Capstone Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 4 quarters since.
Capstone Asset Management's Alnylam Pharmaceuticals position peaked at $343K in Q3 2013.
226 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.